# A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia

> **NCT06821945** · PHASE2 · RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 120 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** BR5402A
- **DRUG:** BR5402A-1
- **DRUG:** BR5402B
- **DRUG:** BR5402B-1
- **DRUG:** BR5402C
- **DRUG:** BR5402C-1
- **DRUG:** BR5402D
- **DRUG:** BR5402D-1

## Key facts

- **NCT ID:** NCT06821945
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06821945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06821945, "A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06821945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*